Physician profile
Roberta S Lay
NPI 1154488955
$2,299.88
in general payments reported to CMS, 2019-2025
17 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 75% of Gastroenterology (Registered Nurse) providers received nationally (typical 2025 total: $239).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.17 · 2022: $220 · 2023: $441 · 2024: $548 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.24 | 2022-2025 | |
| Gilead Sciences, INC. | $378.38 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $231.54 | 2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.01 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $183.23 | 2021-2025 | Entyvio, Eohilia, Hyqvia |
| Janssen Biotech, INC. | $143.13 | 2022-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $73.61 | 2022-2023 | |
| Genzyme Corporation | $69.74 | 2022-2025 | |
| Celgene Corporation | $64.43 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $58.75 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $46.58 | 2021 | |
| Madrigal Pharmaceuticals | $44.44 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $28.93 | 2022 | |
| Lilly USA, LLC | $25.02 | 2025 | Omvoh |
| Pfizer INC. | $20.59 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $19.83 | 2024 | Iqirvo |
| Teva Pharmaceuticals USA, INC. | $17.43 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.